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tis. The involvement of cysteinyl leukotrienes (LT) in the etiology of
glomerulonephritis (ON) was investigated in a rat model of nephrotoxic
serum nephritis in which renal function, morphology, LTC4 synthase
activity and urinary cysteinyl LT excretion were monitored over seven
days. Significant alterations in renal function and morphology were
evident on day 1 in nephritic rats, with a 12% decline in creatinine
clearance, a greater than three-fold increase in urinary protein excretion
and histologic evidence of basement membrane thickening. Urinary LTC4
excretion in the nephritic rats was elevated at this time to 140 38 pg/hr(P < 0.01) compared to undetectable levels in control animals. On days 3
and 7, while proteinuria intensified and glomerular filtration remained
depressed, LTC4 excretion declined 14% (NS) and 79% (P < 0.05),
respectively. The temporal changes in urinary LTC4 excretion were
paralleled by concomitant alterations in LTC4 synthase activity in renal
cortical inicrosomes, where an 84% (P < 0.01) drop in enzyme activity
occurred from day 1 to day 7 in the nephritic group. This data provides the
first measurement of urinary cysteinyl LT excretion and altered LTC4
synthase activity in a model of experimental ON and supports an early role
for LT's in the development of subsequent functional changes.
Leukotrienes (LT), 5-lipoxygenase (5-LO) derived members of
the eicosanoid family, may play an important role in the patho-
physiology of glomerulonephritis (GN). These oxidative products
of arachidonic acid metabolism are believed to mediate the
alterations in renal hemodynamics and filtration which occur in
various nephritides including nephrotoxic serum nephritis (NSN)
[1, 2], passive Heymann nephritis (PHN) [3, 4] and murine lupus
[5]. Synthesis of LTs is initiated through phospholipase A2
mediated release of arachidonic acid from membrane phospho-
lipids [6]. Liberated arachidonic acid is converted to LTA4 by
5-LO in conjunction with 5-lipoxygenase activating protein
(FLAP), these proteins being present largely in cells of myeloid
lineage only [7—9]. LTA4, an unstable epoxide, is rapidly con-
verted by two distinct enzymes (LTA4 hydrolase and LTC4
synthase) into diverging metabolic pathways. The formation of
LTB4, a potent chemotactic agent which stimulates leukocyte
aggregation, adhesion to endothelial cells and release of reactive
oxygen intermediates is catalyzed by LTA4 hydrolase [10, 11]. This
enzyme has been purified from a variety of cell types including
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granulocytes and macrophages, as well as non-myeloid tissue such
as glomerular endothelial and mesangial cells [12].
Conjugation of LTA4 with glutathione is catalyzed by LTC4
synthase, which has also been identified in both cell lines and
tissues [13, 14], including rat renal microsomes (manuscript in
preparation). Biotransformation of LTC4 to LTD4 is mediated by
y-glutamyl transpeptidase [15] and to LTE4 via cytosolic dipepti-
dases [16]. In the rat, inactivation of cysteinyl LTs occurs in
the liver, through the acetylation of LTE4 to N-acetyl-LTE4
(NAcLTE4), followed by subsequent o- and a-oxidation [17, 18].
The predominately inactive metabolite, NAcLTE4, is excreted
primarily in the bile. Recent evidence has indicated, however, a
renal site of NAcLTE4 formation. Fauler et al have demonstrated
the metabolism of LTC4 to LTE4 in cultured glomerular cells and
the formation of NAcLTE4 by renal tubular cells in culture [19].
Metabolism of cysteinyl LTs, but not their filtration, was found to
be protein dependent, with inhibition of LTE4 N-acetylation in
the presence of 5% albumin. Conditions of enhanced protein
excretion may therefore, alter the profile of urinary LT excretion.
The kidney itself is sensitive to infusion of LTC4 and LTD4 [20].
Micropuncture studies by Badr, Brenner and Ichikawa [21] have
established the potent and independent effects of LTD4 on
glomerular function as causing both an increase in efferent
arteriolar resistance and a decrease in the ultrafiltration coeffi-
cient. The latter find is likely due to the in vitro demonstration of
mesangial cell contraction in the presence of LTC4 [22].
Enhanced renal LT formation in models of experimental GN
has been described. Early studies by Lianos [2] and Cattell et al
[23] demonstrated increased renal LTB4 formation by isolated rat
glomeruli and cortical homogenates. The correlation between
neutrophil infiltration and glomerular LTB4 synthesis has been
well defined, as has the requirement for complement activation [2,
24]. Indeed, complement-derived anaphylatoxin (C5a) appears to
mediate its pathological effects on the renal vasculature through
the stimulation of cysteinyl LT synthesis [25]. Pharmacological
blockade of the LTD4 receptor with specific receptor antagonists
resulted in the improvement of GFR and a decrease in proteinuria
[1,4], and supports a causal role for cysteinyl LTs in the development
of GN. Since glomerular cells lack the 5-LO enzyme essential for
LTA4 formation, renal synthesis of LTs may involve the transport of
LTA4 from infiltrating leukocytes to native glomerular cells [26, 27].
Synthesis and release of LTA4 from migrating PMNs would provide
renal endothelial and/or mesangial cells with the substrate required
for subsequent local LT biosynthesis.
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We have directed our investigations to the measurement of
urinary cysteinyl LT excretion in a rat model of experimental GN,
in an effort to quantify renal LT formation in vivo. Recent
pharmacological studies have reinforced the important mitogenic
role of cysteinyl LTs (as opposed to LTB4) in glomerular mesang-
ial cell proliferation accompanying nephritis [28] and renal trans-
plant rejection [29]. However, all measurements of LTs in rat
models of nephritis have indicated increased LTB4 production
and, thus far, have been unable to demonstrate enhanced cysteinyl
LT formation. We also investigated renal LTC4 synthase in our
nephritis model and report, for the first time, alterations in LTC4
synthase activity in a disease state.
Methods
Animals
Sprague-Dawley male rats (Charles River, St. Constant, Que-
bec, Canada) weighing 300 20 grams were maintained on
standard rodent chow (PMI Feeds mc, Richmond, Indiana,
USA), containing no less than 22.5% protein, and tap water ad
libitum. All procedures were conducted in accordance with Cana-
dian Council of Animal Care (CCAC) guidelines.
Chemicals
Phosphate-buffered saline (PBS), sucrose, ethylenediaminetet-
raacetic acid (EDTA) (disodium salt), glutaraldehyde, reduced
glutathione (GSH) and rat serum albumin (essentially fatty acid
free) were purchased from Sigma (St. Louis, Missouri, USA).
Formalin and ethyl ether were purchased from Fisher Scientific.
Analytical grade KCI was obtained from BDH, while potassium
phosphate, glacial acetic acid and sodium hydroxide were from
American Chemicals Ltd., (Montréal, Quebec, Canada). Re-
agents for protein determination and bovine y-globulin standard
were purchased from Bio-Rad Laboratories (Richmond, Califor-
nia, USA). Monoclonal antibodies to LTE4 were obtained from
the Weizman Institute of Science, Rehovot, Israel. LTA4 methyl
ester and cysteinyl LT standards were synthesized by the Medic-
inal Chemistry Department at the Merck Frosst Centre for
Therapeutic Research. Hydrolysis of LTA4 methyl ester with
NaOH, as described by Nicholson et a! [13], yielded the free acid
form of LTA4, which was then used as stock solution. Dupont
NEN Research Products (Wilmington, Delaware, USA) provided
(14, 15, 19, 20-3H(N)) leukotriene E4. [3H]-NAcLTE4 was pre-
pared by N-acetylation of [3H]-LTE4 by a modified method of
Bernström and HammarstrOm [30] whereby 0.5 ml [3H]-LTE4 was
mixed with an equal volume of MeOH, followed by the addition
of 100 1 M K2C03 and 100 l acetic anhydride. The mixture was
then incubated at ambient temperature for 10 minutes with
constant stirring. Addition of acetylation reagents was repeated
twice, such that overall incubation time was 30 minutes. The
reaction was terminated with the addition of 200 tl 5 N formic
acid and the mixture extracted to remove impurities using a Sep
Pak C-18 cartridge, as described below. An aliquot of the radio-
active mixture was "spiked" with cold NAcLTE4 and the retention
times compared by HPLC (Novapak C-18 column, 13.9 X 150
mm, 4 m particle size (Waters Associates, Milford, Massachu-
setts, USA), mobile phase of MeOH:1% wttvoi ammonium
acetate buffer containing 1 mii EDTA, pH 5.4 (Buffer B; 60:40
vol/vol); flow rate of 1 mI/mm) and using a Berthold LC-506 flow
through radioactivity monitor. All solvents required for chromato-
graphic analysis were of HPLC grade.
Induction of anti-GBM nephritis
Nephritis was induced in rats by tail vein injection of approxi-
mately 1 ml of rabbit serum (130 mg protein/mi) containing
anti-rat GBM antibodies. Rabbit serum was prepared for injection
in the manner described by Unanue and Dixon [31]. In brief, adult
New Zealand White rabbits were immunized with 25 mg/mi
lyophilized rat cortical basement membrane which had been
reconstituted in complete Freund's adjuvant. Following periodic
boosting with additional antigen, the rabbits were bled and the
sera frozen at —20°C for shipping (Hazelton Research Products,
Denver, Pennsylvania, USA). Prior to administration, the sera was
decomplemented by heating at 56°C for two hours, adsorbed
overnight against washed rat red blood cells to remove non-
specific reactivity and stored at —20°C. Pre-immunized rabbit sera
was prepared in a similar fashion for adminstration to control rats.
The study interval ranged from 0 to 7 days.
Renal firnction studies and histology
Blood and urine were collected at varying time points for renal
function studies. Rats were placed in individual plexiglass meta-
bolic cages (Nalgene) without food, but with tap water ad libitum,
for a 24-hour urine collection. Following collection of urine,
animals were anaesthetized with ethyl ether and blood obtained
via cardiac puncture. A renal function profile was obtained
through analysis of plasma and urine by conventional methods to
determine creatinine clearance (Car), blood urea nitrogen
(BUN), the clearance of sodium (CNa) and potassium (CK) and
their respective fractional excretions (1Na and FEE). Animals
were then euthanized by cervical dislocation while still under
anaesthesia.
Urinary protein concentration was measured colorimetrically at
595 nm (Beckman DU-7 Spectrophotometer) using Bio-Rad
reagents and following the method described by Bradford [32].
Rat kidneys, removed immediately after sacrifice, were bi-
sected, decapsulated and fixed in either 10% formalin or 5%
glutaraldehyde for hematoxylin and eosin staining or electron
microscopy, respectively. The kidneys were evaluated by a pathol-
ogist blinded to the treatment group or study interval.
Renal microsomal studies
Separate studies were conducted to determine LTC4 synthase
activity in rat cortical microsomes (manuscript in preparation).
Briefly, kidneys from ethyl ether anaesthetized rats were rapidly
removed, bisected, decapsulated and placed in ice cold 1.15% KCI
solution, where the medulo-papillary tissue was macroscopically
dissected away. Cortical microsomes were prepared by differential
centrifugation at 4°C, based on a modification of the method of
Rush et al [33]. Cortical tissue was homogenized in 5 ml 100 mM
PBS containing 5.4 mM EDTA and 0.25 M sucrose, using the
Omni-1000 homogenizer (Omni International, Waterbury, Con-
necticut, USA), followed by 1:8 vol/vol dilution with additional
buffer. The homogenate was centrifuged at 1000 X g for 15
minutes and the supernatant recentrifuged at 10,000 X g for an
additional 15 minutes to remove cellular and non-cellular debris.
The supernatant was then centrifuged at 105,000 X g for 60
minutes and the pellet (comprising the microsomal fraction)
resuspended with 66 mi PBS to a final concentration of 10 to 20
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Table 1. Temporal response of renal parameters in control and nephritic rats over 7 days
Dayl Day3 Day7
Control GN Control ON Control ON
CulImin/1OOgbodywt
BUN mmol/liter
458± 16
6.0 0.2
404±14a
6.2 0.4
493± 14
5.5 0.2
4l2±l9'
6.6 0.3k'
438± 11
5.8 0.1
390±13°
7.4 04b
CN pi/min 3.93 0.29 2.31 0.24° 4.23 0.22 2.29 0.18° 4.23 0.32 3.15 02gdNa 0.36 0.03 0.23 0.02° 0.35 0.02 0.22 0.02° 0.34 0.02 0.3 0.03
CK p1/mm 330 30 278 17 410 33 326 17° 377 27 366 3Ø
FEK % 29.5 1.9 26.5 1.5 33.3 2.4 30.9 1.4 30.1 1.5 33.5 2.4
Values are expressed as mean SEM, with an average of 18 to 20 animals per group. Abbreviations are: Ccr, creatinine clearance; BUN, blood urea
nitrogen; CNa, sodium clearance; FENa, fractional excretion of sodium; CK, potassium clearance; FEK, fractional excretion of potassium.
a p < 0.05, b < 001, C P < 0.001 for comparison of nephritic rats (GN) with time-matched controls
d P < 0.05 for comparison of nephritic groups on day 7 vs. day 3
P < 0.05 for comparison of nephritic groups on day 7 vs. day 1
mg protein/mi. Microsomes were stored at —80°C. LTC4 synthase
activity was determined using the method of Nicholson Ct al [13],
with minor adjustments. At the time of assay, microsomes were
thawed and diluted to 5 mg/mi of microsomal protein with 0.1 M
potassium phosphate buffer, pH 7.4, in a final incubation volume
of 150 JAI containing 50 mM serine-borate complex, 10 mM GSH
and 40 jLM LTA4. An initial concentration of LTA4 (10 times the
final incubation concentration) was prepared by evaporating an
aliquot of LTA4 (free acid) stock under nitrogen, resuspending
LTA4 in 0.05% EtOH and diluting it with rat serum albumin (5
mg/mi). The microsomal mixture was incubated for 10 minutes at
25°C, the reaction was stopped with an equal volume of acetoni-
trile:methanol:acetic acid (50:50:1 vol/vol) and following a 30
minute incubation at 4°C, the mixture was centrifuged for 15
minutes at 16,000 x g. LTC4 formation was measured in the
supernatant by isocratic reverse-phase HPLC (Waters Associ-
ates), with a mobile phase consisting of acetonitrile:methanol:
water:acetic acid (28:14:54:1, vol/vol) at a flow rate of 1 mi/mm,
and is expressed as pmol LTC4 formed min' mg protein .
Quantification of urinary leukotriene excretion
Cysteinyl LTs were quantified from rat urine using a modifica-
tion of the method of Tagari et a! [34]. A 5 ml aliquot of fresh
urine was alkalinized with 10 1.d per ml of 10 N NaOH and stored
at —80°C. At the time of extraction, urine was acidified with 10 .d
per ml of glacial acetic acid and passed through Sep-Pak C-18
cartridges (Waters Chromatography Division) previously condi-
tioned with 10 ml MeOH and 10 ml of water. The cartridges were
washed with 15 ml Buffer B and the LTs eluted with 3 ml MeOH.
Samples were dried under vacuum (Speedvac, Savant) and recon-
stituted in 650 l MeOH. The samples were centrifuged at 16,000
X g for two minutes at 4°C and a 200 pA aliquot was then injected
onto a reverse-phase HPLC (Waters Associates). Leukotrienes
were resolved isocratically with a mobile phase consisting of
MeOH:Buffer B (70:30 vol/vol) from an Alitech Adsorbosphere
(Ailtech Associates, Deerfield, Illinois, USA) UHS C-18 column
(4.6 X 150 mm, 5-sm particle size) at a flow rate of 1 mi/mm. A
three minute pass-through was allowed, followed by collection of
the subsequent eighteen one-minute fractions. Retention times of
LT standards were determined for each batch of samples assayed.
To determine the amount of LT present in each fraction,
radioimmunoassay (RIA) was performed using a rat monoclonal
antibody directed against LTE4, as described by Tagari et al [35,
36]. A standard curve was prepared ranging from 0 to 4 ng LTE4,
I I
Day 1 Day 2 Day 3 Day 7
Fig. 1. Unnaiy protein excretion in control () and nephritic () rats.
Protein excretion was enhanced in nephritic compared to control rats,
* P< 0.05, P < 0.001. In the nephritic animals a progressive increase
in proteinuria was evident over 7 days, § P < 0.05 for nephritic groups on
day 3 vs. days 1 and 2 and day 7 vs. days 1, 2 and 3. Values are expressed
as mean SEM, with an average of 18 to 20 animals per group.
and with a lower limit of detectability of 3 pg/ml for the assay.
Cross-reactivities to the LTE4 antibody were previously deter-
mined by competitive binding assays with known amounts of cold
LTC4, LTD4 and NAcLTE4, to be 470, 296 and 64%, respectively
[37]. Urinary LT excretion was expressed as pg/hr.
Statistical analysis
Within group comparisons were performed using the Students
t-test, while comparisons of more than two groups utilized
ANOVA and t-tests using Bonferroni confidence intervals for
multiple comparisons. Data which were not distributed normally
was analyzed non-parametrically using the Mann-Whitney U-test.
Results
Renal function studies
A decline in renal function was evident early in this model of
experimental glomerulonephritis (GN). Glomerular filtration was
significantly lower in nephritic rats on day 1, with a 12% drop in
Cr compared to controls (Table 1). While filtration remained
impaired on days 3 and 7 (relative to controls), there was no
progressive deterioration in CCr over the duration of the study. A
1:
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Fig. 2. Morphological evidence of glomentlar injuty in nephritic rats on day 1. (A) Glomerular cells from time-matched control rat showing normal
epithelial and endothelial cell morphology. (B) Damage to glomerular epithelial cells in a nephritic rat includes subendothelial electron-dense deposits,
splitting and thickening of basement membrane (upper arrow) and fusion/loss of foot processes (lower arrow). (Magnification X 7500).
fall in sodium and potassium excretion was present on days 1 and
3, which may reflect a glomerulotubular feedback response to
impaired glomerular filtration (Table 1). Sodium clearance fell
40% on day 1, from 3.91 0.29 p1/mm in control animals to
2.31 0.24 p1/mm in the nephritic group (P < 0.001), while FENa
decreased 36%, from 0.36 0.03 % to 0.23 0.02% (P < 0.001).
By day 7, however, sodium reabsorption appeared to normalize,
with a rise in FENa to 0.30 0.03% (P < 0.05). Similar changes,
but of lesser magnitude were seen in potassium excretion.
Urinary protein excretion followed a pattern characteristic of
antibasement membrane GN. Protein excretion in nephritic rats
was elevated three fold to 27 4 mg 24 hr1 100 g body wt1
on day 1, declined slightly on day 2 to 16 0.5 mg 24 hr1 100
g body wt 1, then rose progressively over the study interval to
140 5.7 mg 24 hr1 100 g body wF' on day 7, indicating
severe proteinuria (Fig. 1). A decrease in urinary output occurred
only on day 7, at which time the 24-hour urine volume was 22
2.5 ml in the nephritic rats compared to 30 3.1 ml in the controls
(P < 0.05). Body weight did not differ significantly between the
groups at any time.
Renal histology
Electron microscopy of glutaraldehyde fixed renal tissue con-
firmed a model of anti-GBM GN. The normal glomerular ultra-
structure in control animals on day 1 (Fig. 2A) was in sharp
contrast to that found in nephritic rats where evidence of base-
ment membrane thickening and splitting, the presence of suben-
dothelial electron-dense inclusion bodies and fusion and/or loss of
epithelial foot processes was present (Fig. 2B). Hematoxylin and
eosin staining indicated an increase in neutrophil infiltration,
followed by lymphocytic infiltration and the appearance of hyalin
droplets and casts on day 3 (data not shown). By day 7 extracel-
lular matrix deposition increased and cellular proliferation was
present. Control rats injected with pre-immunized rabbit sera
demonstrated slight non-specific electron-dense deposition on day
1. Renal morphology, as assessed by light and electron microscopy
in the control group on days 3 and 7, did not differ from
age-matched naive rats (data not shown).
Urinary leukotriene excretion
A significant increase in urinary cysteinyl leukotriene excretion,
particularly LTC4, was found in the nephritic groups relative to
controls. Figure 3A demonstrates the rise in LTC4 and LTD4
excretion which occurred on day 1, with peak LTC4 excretion at
140 38 pg/hr (P < 0.01). On day 3 (Fig. 3B) excretion of both
LTC4 and NAcLTE4 was significantly enhanced in nephritic
animals, while on day 7 only LTC4 excretion remained signifi-
cantly elevated at 29 13 pg/hr (P < 0.05; Fig. 3C).
A time-dependent decrease in urinary cysteinyl LT excretion
was evident in nephritic rats over the study interval (Fig. 4). LTC4
excretion dropped 14% from day 1 to day 3 and 76% from day 3
to day 7 (P < 0.05). A very different excretion profile occurred in
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Fig. 4. Profile of iuinaiy cysteiny! leukotriene (LT) excretion in nephrisic
met. A decrease in urinay LTC4 excretion occurred between days 1 and 7,
while enhanced excretion of urinry NAcLTE4 wasonly evident on day 3.
Significance is denoted as * P C 0.05 for LTC4 excretion on day 7
compared to day I. and P C 0.05 for NAcLTE4 excretion on days 1 and
7 compared to day 3. Values are expressed as mean SENt, with an
average of 5 to 15 rats per group. Symbols are: (U) LTC4; (0) LTD4; (0)
LTE4; () NAcLTE4.
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microsomes. Renal microsomes were prepared as described in Methods.
Microsomes were incubated for 10 minutes at 25°C in the presence of 40
ILM LTA4 and 10 mM OSH. Values were expressed as mean SENt, with
an average of 3 to 8 rats per group. * Pc 0.05, ** Pc 0.01 for control vs.
nephritic groups, and P c 0.05 for nephritic rats on day 7 vs. day I.
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Fig. 3. Urinaty excretion of cysteinyl leukotrienes (LT) in control (0) and
nephritic rats (fl), Urinary LT excretion, as measured by HPLC-RIA, on
(A) day 1, (B) day 3 and (C) day 7. Values are expressed as mean SEM,
with an average of 5 to 15 rats per group. * P < 0.05, ** P < 0.01 for
control vs. nephritic rats.
the control group. LTC4 and NAcLTE4 were not detected in the
urine of control rats at any time (Fig. 3). The assumption was
made therefore, that urinary LTC4 excretion in naive rats, prior to
immunization with rabbit serum, was also below detectable limits.
Excretion of LTD4 appeared to increase on days 3 and 7; however,
these changes were not statistically significant.
microsomes of nephritic and control rats over seven days is
presented in Figure 5. LTC synthase activity from nephritic
animals was significantly increased relative to controls on day 1
[15.38 2.78 vs. 8.72 1.47 pmol LTC4 formed min' mg
protein1 (P < 0.05)]. On day 3, enzyme activity was similar to
time-matched controls, but by day 7 had dropped significantly to
2.62 0.41 pmol LTC4 formed min' mg protein1 (P < 0.01)
compared to 9.7 1.39 pmol LTC4 formed min mg pro-
tein1 for control animals. Enzyme activity in control rats did not
differ from that present in age-matched naive animals (9.54
1.60 pmol LTC4 formed min1 mg protein1.
The changes in LTC4 synthase activity in renal microsomes of
nephritic animals revealed a time-dependent alteration in enzyme
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Fig. 6. Comparison of renal microsomal LTC4 synthase activity with urina,y
excretion of LTC4 in nephritic rats. Temporal responses in enzyme activity
(—•—) and urinaly LTC4 excretion (—0—) were defined as % change
from day 0 control values. Both LTC4 synthase activity and urinary LTC4
excretion were elevated on day 1, relative to controls * P < 0.05, ** P <
0.01. Compared to day 1, there was a slight declined in both parameters on
day 3, and by day 7, significant decreases in enzyme activity and LTC4
excretion were evident, P < 0.05. Each point represents the mean SCM,
with an average of 3 to 15 rats per group.
activity, which paralleled the profile of urinaly cysteinyl LT
excretion (Fig. 6). On day 1, enzyme activity in nephritic rats had
increased by 63% (P < 0.05) compared to day 0 values (and 75%
compared to time-matched controls, P < 0.05). LTC4 synthase
activity in the nephritic animals decreased by 29% on day 3
relative to day 1 values (NS) and by 73% from day 3 to day 7
(P < 0.01). A similar biphasic response was found in urinaly
cysteinyl LT excretion in nephritic rats, with a significant initial
increase in LTC4 excretion on day 1 compared to time-matched
controls, followed by a drop on day 3 and a substantial reduction
(76%, P < 0.05) on day 7 relative to day 1.
Discussion
The potent effects of cysteinyl LTs on renal vascular and
hemodynamic functions, as well as morphological alterations,
have been demonstrated in a number of in vivo [1—4, 21, 24, 25]
and in vitro [20, 22, 28, 29] studies, however, reports of their renal
elimination were lacking. Our investigations of renal LT excretion
have now demonstrated an increase in urinary cysteinyl LT
elimination in a rat model of NSN. A biphasic profile of LT
excretion was noted, with peak LTC4 excretion in the urine
occurring within the first 24 hours following injection of immu-
nized rabbit sera. These results are in keeping with published data
of enhanced glomerular LTB4 synthesis during the same interval
[1, 2, 24, 28]. Analogous to the decline in LTB4 formation
reported at later time points, a decrease in urinary LTC4 excretion
was also found to occur by day 7. However, excretion of LTC4
remained significantly elevated throughout the study interval in
nephritic animals compared to controls which received non-
immune rabbit sera. Increased renal LTC4 formation in nephritic
rats would account, in part, for the ongoing glomerular dysfunc-
tion and proteinuria which developed in these animals. Cysteinyl
LT excretion in control rats was generally below the limits of
detection, a finding consistent with the predicted low levels of LTs
in naive rats [15, 19], and supports a pathological rather than
physiological role for LTs in the kidney. The presence of LTD4
and LTE4 in the urine on days 3 and 7 may reflect either basal
elimination or a non-specific response to rabbit serum proteins.
While the primary means of LT elimination in the rat remains
via the bile, excretion of NAcLTE4 and its w- and /3-derivatives in
the urine can account for 1 to 16% of measured metabolites [38,
18]. Our assessment of cysteinyl LT excretion in nephritic rats,
however, has indicated increased levels of LTC4 in the urine.
There are several possible explanations for this shift in the
excretion profile. Since the cysteinyl LTs are both synthesized and
eliminated by the kidney, hepatic metabolism of circulating LTs
would not be expected to contribute significantly to NAcLTE4
formation. Renal biotransformation of cysteinyl LTs has been
shown to be site-specific and influenced by protein binding, with
5% albumin causing a reduction in renal LTC4 metabolism and
NAcLTE4 excretion in the isolated perfused kidney [19]. Leuko-
trienes are lipophilic compounds stabilized by binding with albu-
min [37], which in turn would affect further metabolism. Another
factor affecting LTC4 biotransformation is the concentration of
LTA4 substrate available. In vitro studies by Claesson and
Haeggstrom [27] have demonstrated that in the presence of
increasing LTA4 concentrations, endothelial cells produced
greater amounts of LTC4, while LTD4 formation continued at a
uniform rate, resulting in the accumulation of LTC4 in the
incubation buffer. At lower doses of LTA4, the formation of LTD4
exceeded that of LTC4 and accounts for the generally low levels of
LTC4 reported previously. Therefore, although urinary NAcLTE4
might reflect typical LT excretion, under pathological conditions
of increased availability of LTA4 (provided by infiltrating leuko-
cytes and macrophage), together with an elevated protein concen-
tration in the glomerular filtrate, the urinary profile would change
to one of LTC4 excretion. Indirect evidence of enhanced LTC4
elimination is provided by the increase in LTC4 formation re-
ported in zymosan-treated peritoneal macrophages [39] and cor-
tical homogenates [5] from nephritic MRL-lpr/lpr mice, as well as
our own studies of enhanced LTC4 synthase activity in nephritic
rat renal microsomes. That a significant elevation in urinary LTC4
excretion is present in nephritic rats, at a time of depressed
enzyme activity, may be a consequence of the increased availabil-
ity of LTA4 substrate (provided by infiltrating or resident macro-
phages).
LTC4 synthase activity in renal microsomes paralleled the
pattern of urinary LTC4 excretion in nephritic rats and may
provide an explanation for the biphasic profile of LT elimination.
The increase in enzyme activity seen within the initial 24 hours
following administration of nephrotoxic rabbit serum may reflect
the increased number of leukocytes present in the kidney at this
time. However, infiltrating macrophages also contain LTC4 syn-
thase, and even a decrease in their relative number (compared to
neutrophils) may not account for the significant decline in enzyme
activity evident on day 7. An alternative explantation would
involve regulation of LTC4 synthase activity by other mechanisms
or factors provided by infiltrating myeloid cells or renal cells.
**
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Recent evidence has demonstrated a protein kinase C (PKC)-
mediated decrease in enzymic activity, possibly due to phosphor-
ylation at the PKC consensus sequence within the N-terminal
region of LTC4 synthase, in the granulocytic HL-60 cell line [40].
Concomitant administration of the PKC inhibitors staurosporine
or bisindolylmaleimide prevented the decline in cysteinyl LT
formation in HL-60 cells which had been caused by activation of
PKC with phorbol myristate acetate (PMA) [40, 41]. It is possible
that phosphorylation of LTC4 synthase in nephritic rats is respon-
sible for the decline in enzyme activity at a time when infiltrating
macrophages are present in the glomerulus. There are several
potential mediators in the nephritic kidney, which may regulate
phosphorylation of LTC4 synthase including PDGF [42], C5b-9
[43] and lipoxins [44]. There is now growing evidence for the
opposing effects of lipoxins and cysteinyl LTs in the kidney
including LXA4-mediated afferent arteriolar dilation and compe-
tition with LTD4 for receptor binding on mesangial cells [44]. The
lipoxin precursor 15-S-hydroxyeicosatetraenoic acid (15-S-HETE)
has been shown to both prevent rat LTB4-mediated neutrophil
migration and to normalize glomerular LTB4 formation in rats
with nephrotoxic serum nephritis [45]. The increase in 15-S-
HETE appeared to correlate with macrophage infiltration (al-
though identification of a cellular source could not be made), and
may account for the suppression of LTB4 formation in nephritic
glomeruli at later time points. Lipoxins, therefore, may play a role
in modulating cysteinyl LT biosynthesis via down-regulation of
LTC4 synthase. Whether the initial increase in enzyme activity is
due to up-regulation of LTC4 synthase, possibly through a mech-
anism involving de-phosphorylation remains speculative.
Cysteinyl LTs play an important role in the pathogenesis and
progression of GN, and likely mediated not only the decline in
renal blood flow and filtration, but also the proliferative changes
which are characteristic of this model. Proliferation of glomerular
endothelial and mesangial cells by LTC4 and LTD4 has been
shown in vitro [22, 46, 47], while in vivo inhibition of LT
biosynthesis in nephritic rats with MK-886 prevented glomerular
cell proliferation [28]. Enhanced urinary excretion of cysteinyl
LTs has been demonstrated in other cases of clinical and exper-
imental renal inflammatory injury such as systemic lupus erythem-
atous [48], hepato-renal syndrome [49] and transplant rejection
[29], and now in our rat model of NSN. Together with evidence of
enhanced LTB4 formation and the renal protective effect of LT
biosynthesis inhibition or receptor blockade by others, the in-
crease in renal LTC4 formation and cysteinyl LT elimination
reported in our rat model of NSN further supports a causal role
for LTs in the development of nephritis. The alteration in renal
LTC4 synthase activity may provide an explanation for the bipha-
sic excretion profile of cysteinyl LTs and suggests a potentially
specific therapeutic target for LT inhibition in glomerular immune
injury. Further investigation of the factors affecting LTC4 synthase
activity in this, as well as other models of nephritis, is now
necessary to define the mechanisms affecting enzyme activity.
Acknowledgments
This work was supported in part by the Medical Research Council
Industrial Studentship award #1550. We thank Dr. Donald Nicholson and
Philip Tagari for their expert advice on leukotriene measurements, Dr.
Madeleine Chagnon, Bio Research Laboratories Ltd., Senneville, Quebec,
Canada, for the pathological evaluation of histological samples and to Ms.
Faith Carr for assistance in the preparation of this manuscript.
Reprint requests to R. Petric, Department of Pharmacology, Merck Frosst
Centre for Therapeutic Research, P.O. Box 1005, Pointe Claire-Dorval,
Canada, H9H 4P8.
References
1. B.nR KF, Scmtnrcmt OF, WASSERMANN M, IcHilawA I: Preservation
of the glomerular capillary ultrafiltration coefficient during rat neph-
rotoxic serum nephritis by a specific leukotriene D4 receptor antago-
nist. J Clin Invest 81:1702—1709, 1988
2. Li&tcos LA: Synthesis of hydroeicosatetraenoic acids and leukotrienes
in rat nephrotoxic serum nephritis. J Clin Invest 82:427—435, 1988
3. Lin'ios LA, NOBLE B, Hucln B: Olomerular leukotriene synthesis in
Heymann nephritis. Kidney mt 36:998—1002, 1989
4. KATOH T, LIAJios LA, FUKUNAGA M, TAKAHA5HI K, BiWR ICE
Leukotriene D4 is a mediator of proteinuria and glomerular hemody-
namic abnormalities in passive Heymann nephritis. J Clin Invest
91:1507—1515, 1993
5. SPURNEY RF, Ruiz P, PI5ETsKY DS, CorvMAH TM: Enhanced renal
leukotriene production in murine lupus: Role of lipoxygenase metab-
olites. Kidney mt 39:95—102, 1991
6. KUDO I, MuItA.IaMI M, HutA 5, INouc K: Mammalian non-pancre-
atic phospholipases A2. Biochim Biophys Acta 1177:217—232, 1993
7. ROUZER CA, KARGMAN 5: Translocation of 5-lipoxygenase to the
membrane in human leukocytes challenged with ionophore A23187.
JBiol Chem 263:10980—10988, 1988
8. MILLER DK, GILLARD JW, VIcICER5 PJ, SA0w5KI 5, LEvEILLE C,
MANcINI JA, CHARLE5ON P, DIXON RAF, FORD-HUTCHIN5ON AW,
FORTIN R, GAUTHIER J-Y, RODKEY 3, ROSEN R, ROUZER C, SIGAL IS,
STRADER CD, EvANs JF: Identification and isolation of a membrane
protein necessary for leukotriene production. Nature 343:278—281,
1990
9. Dxor'i RAF, DIEHL RE, OPA5 F, RAND5 E, VicleuRs PJ, Ev4s.r.is iF,
GILLARD JW, MILLER DK: Requirement of a 5-lipoxygenase-activat-
iog protein for leukotriene synthesis. Nature 343:282—284, 1990
10. F0RD-HuTcHtNsoN AW: Leukotriene B4 in inflammation. Crit Rev
Immunol 10:1—12, 1990
11. RADMARK 0, SHIMIZU T, JORNVALL H, SAMUEL5SON F: Leukotriene
A. hydrotase in human leukocytes. Purification and properties. J Biol
Chem 269:12339—12345, 1984
12. MAKITA N, FUNK CD, IMAI B, HoovER RL, BADR ICE: Molecular
cloning and functional expression of rat leukotriene A4 hydrolase
using the polymerase chain reaction. FEBS Lett 299:273—277, 1992
13. NIcHoLSoN D, ALl A, KLEMBA M, MUNDY NA, ZAMBONI RJ, FORD-
HrrrcHlNsoN AW: Human leukotriene C4 synthase expression in
dimethyl sulfoxide-differentiated U937 cells. J Biol Chem 267:17849—
17857, 1992
14. IsuMI T, HONDA Z, OHI5HI N, KITAMURA 5, Tsucnm 5, SATO K,
SHIMIZu T, SEYAMA Y: Solubilization and partial purification of
leukotriene C4 synthase from guinea pig lung: A microsomal enzyme
with high specificity towards 5,6-epoxide leukotriene A4. Biochim
Biophys Acta 959:305—3 15, 1988
15. ORNING L, HAMMER5TROM 5: Kinetics of the conversion of leuko-
triene C4 by y-glutamyl transpeptidase. Biochem Biophys Res Commun
106:1304—1309, 1982
16. LEE CW, LEwIs RA, COREY U, AusmN KF: Conversion of leukot-
riene D4 to leukotriene F4 by a dipeptidase released from the specific
granules of human polymorphonuclear leukocytes. Immunol 48:27—35,
1993
17. HAGMANN W, DENZLINOER C, Rn 5, WECKSEcKER 0, KEPPLER D:
Identification of the major endogenous leukotriene metabolites in the
bile of rats as N-aeetyl leukotriene F4. Prostaglandins 31:239—251,
1986
18. PERRIN P. ZIRROLLI 3, STENE DO, LELLOUCHE JP, BEAUCORT JP,
MURPHY RC: In vivo formation of /3-oxidized metabolites of leukot-
riene £4 in the rat. Prostaglandins 37:53—60, 1989
19. FAULER 3, WIEMEYER A, YosmzAwA M, SCHUREK HJ, FROLICH JC:
Metabolism of cysteinyl leukotrienes by the isolated perfused rat
kidney. Prostaglandins 42:239—249, 1991
20. Rosnr.rrnAL A, PAcE-AscIAlc CR: Potent vasoconstriction of the
isolated perfused rat kidney by leukotrienes C4 and D4. Can J Physiol
Pharmacol 61:325—328, 1983
Petric and Ford-Hutchinson: Cysteinyl LT excretion in GN 1329
21. BADR KF, BRENNER BM, IcHIwA J: Effects of leukotriene D4 on
glomerular dynamics in the rat. Am J Physiol 253:F239—F243, 1987
22. BARNETT R, GOLDWASSER P, SCHARSCHMIDT L, SCHLONDORFF D:
Effects of leukotrienes on isolated rat glomeruli and cultured mesang-
ial cells. Am J Physiol 250:F838—F844, 1986
23. CArr'ELL V, CooK HT, SMITH J, SALMON JA, MONCADA S: Leukot-
riene B4 production in normal rat glomeruli. Nephrol Dial Transplant
2:154—157, 1987
24. LEFKOWITH JB, NAGAMATSU T, PIPPIN J, SCHREINER GF: Role of
leukocytes in metabolic and functional derangements of experimental
glomerulonephritis. Am J Physiol 261:F213—F220, 1991
25. GLUBINS E, SCHOLOTFMANN K, RAUTERBERG EW, STEINHAUSEN M:
Effects of rC5a on the circulation of normal and split hydronephrotic
rat kidneys. Am J Physiol 265:F96—F103, 1993
26. FEINMARK SJ, CANNON PJ: Endothelial cell leukotriene C4 synthesis
results from intercellular transfer of leukotriene A4 synthesized by
polymorphonuclear leukocytes. J Biol Chem 261:16466—16472, 1986
27. CLAESSON HE, HAEGGSTROM J: Human endothelial cells stimulate
leukotriene synthesis and convert granulocyte released leukotriene A4
into leukotriene B4, C4, D4, E4. Eur J Biochem 173:93—100, 1988
28. Wu SH, LIAN0s LA: Modulatory effect of arachidonate 5-lipoxygen-
ation on glomerular cell proliferation in nephrotoxic serum nephritis.
fLab Clin Med 122:703—710, 1993
29. SPURNEY RF, II3RAHIM S, BUTFERLY D, KLOTMAN PE, SANFILIPPO F,
COFFMAN M: Leukotrienes in renal transplant rejection in rats.
J Immunol 152:867—876, 1994
30. BERNSTROM K, HAMMARSTROM 5: Metabolism of leukotriene E4 by
rat tissues: Formation of N-acetyl leukotriene E4. Arch Biochem
Biophys 244:486—491, 1986
31. UNANUE ER, DixoN FJ: Experimental glomerulonephritis: Studies on
the interaction of nephrotoxic antibodies with tissues of the rat. J Exp
Med 21:697—714, 1965
32. BRADFORD MM: A rapid and sensitive method for the quantification
of microgram quantities of protein utilizing the principle of protein
dye binding. Anal Chem 72:248—254, 1976
33. RUSH GF, MAlTA K, SLEIGHT SD, HooK JB: Induction of rabbit renal
mixed function oxidases by phenobarbital: Cell specific ultrastructural
changes in the proximal tubule. Proc Soc Exp Biol Med 172:430—439, 1983
34. TAGARI P, ETHIER D, CARRY M, KORLEY V, CHARLESON 5, GIRARD
Y, ZAMBONI R: Measurement of urinary leukotrienes by reverse phase
liquid chromatography and radioimmunoassay. Gun Chem 35:388—
391, 1989
35. TAGARI P, BECKER A, BRIDEAU C, FRENETITE R, SADL V, THOMAS
EH, VIcKERs P. FORD HUTCHINSON AW: Leukotriene generation and
metabolism in dogs: Inhibition of biosynthesis by MK-0591. J Phar-
macol Exp Therap 265:416—425, 1993
36. TAGARI P, ETHIER D, FORD HUTCHINSON A, CIRIN0 M: Appplication
of reversed phase liquid chromatography to the analysis of sulfidopep-
tide leukotrienes in pig bile. Biomed Chromat 4:38—42, 1990
37. FOSTER A, FITZSIMMONS B, ROKACH J, Larrs LG: Metabolism and
excretion of peptide leukotrienes in the anaesthetized rat, Biochim
BiophysActa 921:486—493, 1987
38. FITZPATRICK FA, MORTON DR, WYNALDA MA: Albumin stabilizes
leukotriene A4. J Biol Chem 257:4680—4683, 1982
39. S.ki'rroo TJ, MORRIS DH, MURPHY RC, BAARR RC: Aberrant
production of leukotriene C4 by macrophages from autoimmune-
prone mice. J Exp Med 168:783—788, 1988
40. KARGMAN 5, All A, VAILLANCOURT JP, EVANS JF, NICHOLSON DW:
Protein kinase C dependent regulation of sulfidopeptide leukotriene
biosynthesis and leukotriene C4 synthase in neutrophilic HL-60 cells.
Mol Pharmacol 45:1043—1049, 1994
41. AL.! A, FORD-HUTCHINSON AW, NICHOLSON DW: Activation of pro-
tein kinase C down regulates leukotriene C4 synthease activity and
attenuates cysteinyl LT production in an eosinophilic substrain of
HL-60 cells. J Immunol (in press)
42. ROZENGURT E: Early signals in the mitogenic response. Science
234:161—166, 1986
43. CYBULSKY AV, BONVENTRE JV, QUIGG RJ, LIEBERTHAL W, SALANT
DJ: Cytosolic calcium and protein kinase C reduce complement-
mediated glomerular epithelial injury. Kidney mt 38:803—811, 1990
44. SHERHAN CN: Lipoxins: Eicosanoids carrying intra- and extracellular
messages. J Bioenerg Biomemb 23:105—122, 1991
45. FISHER DB, CHRISTMAN JW, BArR KF: Fifteen-S-hydroxyeicosatet-
raenoic acid (15-5-HETE) specifically antagonizes the chemotactic
action and glomerular synthesis of leukotriene B4 in the rat. Kidney mt
41:1155—1160, 1992
46. BAUD L, SRAER J, PEREZ 1, NIVEZ MP, ARDAILLOU R: Leukotriene C4
binds to human glomerular epithelial cells and promotes their prolif-
eration in vitro. J Clin Invest 76:374—377, 1985
47. BAUD L, PEREZ J, CHARQUI G, CRAGOE EJ, ARDAILLOU R: Leukot-
riene D4-induced proliferation of glomerular epithelial cells: PKC-
and Na-H exchanger-mediated response. Am J Physiol 257:C232—
C239, 1989
48. HACKSHAW Ky, VOELKEL NF, TIIOHAS RB, WESTCOTF JY: Urine
leukotriene E4 levels are elevated in patients with active systemic
lupus eiythematous. J Reumatol 19:252—258, 1992
49. HUBER M, KASTNER 5, SCI-IOLMERICH J, GEROK W, KEPPLER D:
Analysis of cysteinyl leukotrienes in human urine: Enhanced excretion
in patients with liver cirrhosis and hepatorenal syndrome. Eur J C/in
Invest 19:53—60, 1989
